{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:18:54Z","timestamp":1765772334445,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clinthera.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:44:18Z","timestamp":1436316258000},"page":"1955-1965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Activity of UR-1505 in Atopic Dermatitis: A Randomized, Double-blind Phase II Exploratory Trial"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"2007-002550-27","registry":"10.18810\/euctr"}],"author":[{"given":"Roser","family":"Vives","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sarasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Millier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinthera.2015.06.005_bib1","doi-asserted-by":"crossref","first-page":"e39803","DOI":"10.1371\/journal.pone.0039803","article-title":"Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990\u20132010: A Systematic Review of Epidemiological Studies","volume":"7","author":"Deckers","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2015.06.005_bib2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/archdermatol.2011.100","article-title":"New Drugs and New Molecular Entities in Dermatology","volume":"147","author":"Eaglstein","year":"2011","journal-title":"Arch Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.clinthera.2015.06.005_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2230.2012.04336.x","article-title":"Guidance on the diagnosis and clinical management of atopic eczema","volume":"37","author":"Baron","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl. s1","key":"10.1016\/j.clinthera.2015.06.005_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjd.12975","article-title":"Immunological and molecular targets of atopic dermatitis Treatment","volume":"170","author":"Wollenberg","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.clinthera.2015.06.005_bib7","unstructured":"European Medicines Agency, 2006. European Medicines Agency recommends cautious use of Protopic\/Protopy and Elidel. EMEA\/98882\/2006. Last consulted on 6th March 2015 at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500014840.pdf"},{"key":"10.1016\/j.clinthera.2015.06.005_bib8","unstructured":"Pediatric Advisory Committee Meeting presentation by Marilyn R. Pitts, Safety Evaluator, Office of Drug Safety, FDA Center for Drug Evaluation and Research. Post-Marketing Cases of Tumors Reported with the Topical Immunosuppressants (Calcineurin Inhibitors), 15 Feb 2005. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/slides\/2005-4089s2.htm. Accessed 05 May 2015."},{"key":"10.1016\/j.clinthera.2015.06.005_bib9","unstructured":"Pediatric Advisory Committee presentation from Barbara Hill, Division of Dermatologic and Dental Drug Products, FDA Center for Drug Evaluation and Research. Topical immunosuppressants (calcineurin inhibitors)\u2014animal toxicology, 15 Feb 2005. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/slides\/2005-4089s2_01_06_Hill.ppt. Accessed 5 May 2015."},{"key":"10.1016\/j.clinthera.2015.06.005_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic Dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib11","doi-asserted-by":"crossref","unstructured":"Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment. ISRN Allergy 2014; 2014: Article ID 354250, 7 pages.","DOI":"10.1155\/2014\/354250"},{"key":"10.1016\/j.clinthera.2015.06.005_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/mol.107.035212","article-title":"UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells","volume":"72","author":"Roman","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib13","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.bcp.2007.07.026","article-title":"The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition","volume":"74","author":"Bail\u00f3n","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ibd.20381","article-title":"UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis","volume":"14","author":"Bail\u00f3n","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2015.06.005_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1254\/jphs.08292SC","article-title":"The new salicylate derivative UR-1505 modulates the Th2\/humoral response in a dextran suphate model of colitis that resembles ulcerative colitis","volume":"109","author":"Bail\u00f3n","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2015.06.005_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The UK Working Party\u2019s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis","volume":"186","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.clinthera.2015.06.005_bib18","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/jid.2013.19","article-title":"Climatic factors are associated with childhood eczema prevalence in US","volume":"133","author":"Silverberg","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.0022-202X.2005.23625.x","article-title":"Seasonality in symptom severity influenced by temperature or grass pollen: results of a panel study in children with eczema","volume":"124","author":"Kr\u00e4mer","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib21","unstructured":"European Medicines Agency. Protopic Summary of Product Characteristics. Last consulted on 06 March 2015 at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000374\/WC500046824.pdf"},{"key":"10.1016\/j.clinthera.2015.06.005_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.06.005_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.2005.06438.x","article-title":"Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial","volume":"152","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib24","first-page":"666","article-title":"Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis","volume":"10","author":"Frankel","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clinthera.2015.06.005_bib25","first-page":"805","article-title":"Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis","volume":"103","author":"Van Leent","year":"1998","journal-title":"Arch Dermatol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:23Z","timestamp":1758962963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0149291815008590"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.06.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Activity of UR-1505 in Atopic Dermatitis: A Randomized, Double-blind Phase II Exploratory Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}